Tenet Healthcare Corp. (THC): 2Q26 Recap: Optimized Execution on Compelling L-T Strategy Transforms 2Q Earnings into a Decisive Stock Catalyst

Research evidence excerpt

Tenet Healthcare Corp. (THC): 2Q26 Recap: Optimized Execution on Compelling L-T Strategy Transforms 2Q Earnings into a Decisive Stock Catalyst

Goldman Sachs Tenet Healthcare Corp. (THC)

contraction and related payer mix shifts, but THC continues to position the Hospital

portfolio toward higher acuity services to support pricing / margin growth durability. At

the same time, the ASC platform remains the core growth engine, with benefits from

service line expansion and higher acuity case growth, as evidenced by 10% growth in

ASC joint procedures reported in 2Q26. Overall, we view the quarter as another

conflicting data point on hospital fundamentals, with THC pointing to payer mix, not

utilization, as representing the more important variable for investor debate over the

balance of 2026. But from a company / stock-specific quarter, we view THC’s optimized

execution yielding the most significant event catalyst for investor alpha generation

among the hospital stocks during 2Q26 earnings season.

Key Takeaways from 2Q26 Earnings Call

Following THC’s 2Q26 earnings results, we summarize our key takeaways from the quarter and

forward outlook:

n Results in context: Tenet’s 2Q26 results came in significantly ahead of consensus at

the EBITDA line, reflecting continued strength in the Ambulatory Care (USPI)

business, favorable core Hospital performance, and a Medicaid supplemental

revenue true-up. Consolidated adjusted EBITDA of $1,304 million exceeded Street

expectations by ~14%, driven primarily by the Hospital segment, with strong

adjusted admissions and pricing (inclusive of Medicaid SDPs). In the ASC business,

THC reported adjusted EBITDA of $542 million with EBITDA margins of 39.0%.

Same-facility revenue growth of 5.0% was driven by stronger revenue per case

growth of 6.3% (vs.